All In Biotech

Drug Trial Radar · NCT00941343

Benign Prostatic Hyperplasia in Taiwan

Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin

Last checked: Nov 20, 2026Latest source record: Mar 30, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

362

Actual

Start

Sep 2006

Primary completion

Sep 2008

Study completion Sep 2008

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: * To assess the sexual function of Benign Prostatic Hyperplasia patients Secondary Objective: * To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders * To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic Hyperplasia patients on XATRAL 10mg OD among the different regions * To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the International Index of Erectile Function (IIEF-5) * To assess the onset of action of XATRAL 10mg OD * To assess the peak urinary flow rate * To assess the safety and the tolerability of XATRAL 10mg OD

Conditions

  • Prostatic Diseases

Interventions

  • Alfuzosin (XATRAL® - SL770499)Drug

    One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Male Sexual Health Questionnaire Ejaculation score (MSHQ)Time frame: At week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.